Mike Webb has more than 25 years of experience in life sciences. He specializes in early-stage companies focused on targeted therapeutics and molecular diagnostics. Currently, he is the CEO of CXL Ophthalmics, a Phase 3 company developing a novel treatment for keratoconus. He has been a founder and CEO of biotechnology companies, taking them from seed round funding through venture financing and NASDAQ IPO. He was the CEO of Tyrogenex, a venture-backed company developing an oral treatment for wAMD, CEO of Allegro Diagnostics a venture-backed company acquired by Veracyte that developed a novel diagnostic for lung cancer. He was the CEO of EPIX Pharmaceuticals which grew from a venture-backed startup to be the world leader in discovery and development of pharmaceuticals for diagnostic imaging with MRl. Mr. Webb joined EPIX from CIBA, where he was Senior Vice President, Worldwide Marketing and Strategic Planning. Mr. Webb holds Bachelors degrees in Biochemistry and Economics from the University of Kansas and an MA in International Relations from Sussex University in the UK, completing his thesis on "Pharmaceuticals Policy and the World Health Organization."In addition, Mr. Webb holds an MBA from Kellogg at Northwestern University. He is past chairman of MassBio.